CD19 Antibody (CVID3/429), Novus Biologicals™

CD19

Monoclonal

0.2 mg/mL

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml

B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19 antigen, CD19 molecule, CVID3, Differentiation antigen CD19, MGC12802, T-cell surface antigen Leu-12

Mouse

95 kDa

0.1 mg

Adaptive Immunity, Cytokine Research, Immunology, Innate Immunity, Mesenchymal Stem Cell Markers, Signal Transduction, Stem Cell Lines, Stem Cell Markers

930

Human, Monkey, Primate

Purified

Flow Cytometry, SDS-Page, Immunofluorescence

CVID3/429

Unconjugated

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

CD19

Recombinant human CD19 protein

Protein A or G purified

RUO

Primary

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms

Store at 4C.

IgG1 κ